September 1, 2021

Visus Therapeutics’ Ben Bergo

September 1, 2021
Ophthalmology Management, Volume: 25, Issue: September 2021, page(s): 52

Industry Insider is a timely chat with an ophthalmic industry thought leader.

Ben Bergo is CEO of Visus Therapeutics and executive director of the company’s board. Visus Therapeutics is developing BRIMOCHOL, a fixed combination of brimonidine tartrate and carbachol, to treat presbyopia. Mr. Bergo has more than 20 years’ experience in the life sciences industry, with previous leadership positions at companies including Planet Innovation and Nohla Therapeutics.

Read the full article here.